The results of this phase III KEYNOTE-991 study do not support the addition of pembrolizumab to enzalutamide and ADT for the treatment of mHSPC,” researchers wrote.

The combination of enzalutamide with androgen deprivation therapy (ADT) significantly increases the chance of five-year survival for men with metastatic hormone-sensitive prostate cancer, according to ...

The FDA approved the poly ADP ribose polymerase (PARP) inhibitor in June 2023 in combination with enzalutamide for men with ...

Discover a study that also highlighted that treatment intensification with enzalutamide benefited patients regardless of ...

Five- and eight-year trial data to be presented at ASCO demonstrate durable survival outcomes with Xtandi (enzalutamide) plus ...

Ed Burgess, diagnosed with stage IV prostate cancer, shares his journey of survival thanks to a combination of hormone ...

Dr. Kristen Scarpato explains the role of genetic testing in prostate cancer care, as well as its use in determining ...

Pfizer Inc. (NYSE:PFE) has unveiled major advances in cancer research at the 2025 ASCO Annual Meeting, spotlighting robust ...

Astellas & Pfizer’s Xtandi shows long-term overall survival in metastatic hormone-sensitive prostate cancer: Tokyo Saturday, May 24, 2025, 13:00 Hrs [IST] Astellas Pharma Inc. a ...

Astellas and Pfizer's Xtandi plus ADT showed a decrease in mortality risk in a metastatic hormone-sensitive prostate cancer ...